The last day for trading in Moberg Pharma's warrants of series 2023:1 (TO 2) is today, June 17th, 2024

The last day for trading in Moberg Pharma's warrants of series 2023:1 (TO 2) is today, June 17^th, 2024

Today, June 17^th, 2024, is the last day for trading in Moberg Pharma AB's (publ)'s ("Moberg Pharma" or the "Company") warrants of series 2023:1 (“TO 2”). The exercise period runs until June 19^th, 2024.

In 2023, Moberg Pharma carried out a rights issue of units which was oversubscribed to approximately 130%. Each unit consisted of one (1) ordinary share and one (1) warrant in Moberg Pharma. One (1) warrant of TO 2 entitles the holder to subscribe for one (1) new ordinary share in Moberg Pharma. The subscription price is SEK 18.00 per share.

TO 2 in brief
Each TO 2 entitles the holder to subscribe for one (1) new ordinary share in the Company during the period June 5^th, 2024, up to and including June 19^th, 2024. The subscription price for subscription of ordinary shares with the support of TO 2 is SEK 18.00 per share (corresponding to 70 percent of the volume-weighted average price in the Company's ordinary share during the period from and including May 20^th, 2024, up to and including May 31^st, 2024). If all warrants of TO 2 are exercised for subscription of ordinary shares, the Company will receive approximately SEK 326.4 million in issue proceeds before transaction costs.

Upon exercise of all 18,134,519 TO 2, the Company's share capital will increase by approximately SEK 18,134,519.90. The Company has received subscription intentions, subscription commitments and top guarantee commitments totalling approximately SEK 113.5 million. The top guarantee commitments amount to SEK 77.7 million and the exercise of such commitments will require subscription in a directed issue, to be resolved by the Board of Directors, based on the authorization from the Annual General Meeting on May 14^th, 2024, after the outcome of the exercise of TO 2 has been announced (the “Share Issue”). Through the Share Issue, the share capital may increase by a maximum of approximately SEK 4,316,666.22 by issuing a maximum of 4,136,666 new ordinary shares. Upon full exercise of all TO 2 and the Share Issue, the number of shares will increase by a maximum of 18,997,852. For additional information on the Share Issue and the commitments, please refer to the press release announced by the Company on June 11^th, 2024.

Full terms and conditions for the TO 2 are available on Moberg Pharma’s website, https://www.mobergpharma.com/investors/exercise-warrants.

How the warrants are exercised:

Nominee-registered warrants:
Subscription and payment of new shares, by exercise of warrants, shall be made to the account-holding bank/nominee with which the warrants are registered. The subscription and payment shall be made in accordance with instructions from each such bank or nominee.

Directly registered warrants:
No payment instructions will be sent out. Subscription shall be made through simultaneous cash payment according to instructions on the subscription form. The warrants will then be replaced with interim shares pending registration with the Swedish Companies Registration Office. A subscription form with payment instructions is available on the Company's website, https://www.mobergpharma.com/investors/exercise-warrants, and on Vator Securities AB:s website www.vatorsecurities.se.

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se
Mark Beveridge, Vice President Finance, telephone: +46 76 805 82 88, e-mail: mark.beveridge@mobergpharma.se

About this information
The information was submitted for publication at 08.00 CEST on June 17^th, 2024, through the contact persons above.

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company's asset, MOB-015, is a novel topical treatment for onychomycosis with market approval in 13 EU countries. MOB-015 is available in Sweden under the brand name Terclara^®. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the Company's shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).

Important information
The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Moberg Pharma. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in Moberg Pharma has only been made through the prospectus published by Moberg Pharma on August 14^th, 2023.